SLC5A2 and COVID-19: First, because the COVID-19 pandemic may have altered care of patients with diabetes and these patients may have a higher risk of death due to COVID-19, and to eliminate bias that may be introduced by these and other factors related to COVID-19, we censored participants on February 29, 2020 (before the onset of the pandemic in the US); the results show that the SGLT2 inhibitor arm exhibited less risk of all-cause mortality compared with the sulfonylurea arm.